Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Retrotope RT001-006 Phase 2/3 trial for protection against oxidative damage in the central nervous system

The Retrotope RT001-006 trial involves the study drug RT001, which may protect against lipid peroxidation, the process that is believed to cause disability in many neurodegenerative diseases, including Friedreich’s ataxia.

This study will involve five visits to a research clinic over a 12-month period. Each site visit can be done over multiple days. If you should decide to participate, you will be reimbursed for reasonable travel expenses.

To qualify, you must:

  • Have been diagnosed with Friedreich's ataxia
  • Be between 12 and 50 years old
  • Be able to walk at least 25-feet within 1 minute, with or without an assistive device
  • Not be actively enrolled in another clinical trial
  • Not have participated in the previous RT001 trial

 
For enrollment at Children's Hospital of Philadelphia only -
Please see this attached flyer to contact the study coordinator at CHOP.

For enrollment at our Long Beach, CA site -
Please see this attached flyer to contact the study coordinator.

For enrollment at other sites -
Please see this attached flyer to contact the study coordinator.

 

SHARE

FacebookTwitterLinkedInYoutube
Science B.jpg
Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator